Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5209847
Max Phase: Preclinical
Molecular Formula: C223H315N51O67S7
Molecular Weight: 5006.73
Associated Items:
ID: ALA5209847
Max Phase: Preclinical
Molecular Formula: C223H315N51O67S7
Molecular Weight: 5006.73
Associated Items:
Canonical SMILES: CCCC[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H]2CSCCC(=O)N3CN(CN(C3)C(=O)CCSC[C@@H](C(=O)N[C@@H](CNC(=O)CCc3cn(CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCNC(=O)N[C@H]4CSCCC(=O)N5CN6CN(C5)C(=O)CCSC[C@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc5cccc7ccccc57)NC(=O)[C@@H]5CCCN5C4=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc4c[nH]c5ccccc45)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N4CCC[C@H]4C(=O)N4C[C@H](O)C[C@H]4C(=O)N[C@@H](Cc4c[nH]c5ccccc45)C(=O)N[C@H](C(N)=O)CSCCC6=O)nn3)C(N)=O)NC1=O)C(=O)CCSC[C@H](NC(=O)[C@H](C)NC(C)=O)C(=O)NC([C@@H](C)CC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N2
Standard InChI: InChI=1S/C223H315N51O67S7/c1-9-11-35-148-197(306)256-168(118-346-95-62-181(287)267-123-266-124-268(125-267)182(288)63-96-347-119-169(255-193(302)128(4)235-131(7)277)213(322)260-189(127(3)10-2)217(326)242-152(53-57-185(292)293)199(308)240-150(52-56-184(290)291)195(304)234-111-177(283)237-151(51-54-175(224)281)198(307)243-155(99-133-42-47-140(278)48-43-133)203(312)257-167(117-345-94-61-180(266)286)211(320)244-154(98-132-27-13-12-14-28-132)201(310)236-129(5)194(303)251-162(107-188(298)299)218(327)271-67-24-39-171(271)214(323)248-156(202(311)239-148)100-134-44-49-141(279)50-45-134)212(321)252-163(191(225)300)110-233-176(282)55-46-139-112-270(263-262-139)70-72-333-74-76-335-78-80-337-82-84-339-86-88-341-90-89-340-87-85-338-83-81-336-79-77-334-75-73-332-71-66-230-223(331)259-170-120-348-97-64-183(289)269-122-264-121-265(126-269)179(285)60-93-344-116-166(258-208(317)161(106-187(296)297)247-204(313)157(249-215(324)172-40-25-68-272(172)219(170)328)101-136-31-23-30-135-29-15-16-32-143(135)136)210(319)241-153(58-91-342-8)200(309)238-149(38-21-22-65-229-222(227)228)196(305)246-160(105-186(294)295)207(316)245-158(102-137-108-231-146-36-19-17-33-144(137)146)205(314)253-164(114-275)209(318)261-190(130(6)276)221(330)273-69-26-41-173(273)220(329)274-113-142(280)104-174(274)216(325)250-159(103-138-109-232-147-37-20-18-34-145(138)147)206(315)254-165(192(226)301)115-343-92-59-178(264)284/h12-20,23,27-34,36-37,42-45,47-50,108-109,112,127-130,142,148-174,189-190,231-232,275-276,278-280H,9-11,21-22,24-26,35,38-41,46,51-107,110-111,113-126H2,1-8H3,(H2,224,281)(H2,225,300)(H2,226,301)(H,233,282)(H,234,304)(H,235,277)(H,236,310)(H,237,283)(H,238,309)(H,239,311)(H,240,308)(H,241,319)(H,242,326)(H,243,307)(H,244,320)(H,245,316)(H,246,305)(H,247,313)(H,248,323)(H,249,324)(H,250,325)(H,251,303)(H,252,321)(H,253,314)(H,254,315)(H,255,302)(H,256,306)(H,257,312)(H,258,317)(H,260,322)(H,261,318)(H,290,291)(H,292,293)(H,294,295)(H,296,297)(H,298,299)(H4,227,228,229)(H2,230,259,331)/t127-,128-,129-,130+,142+,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161+,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,189?,190-/m0/s1
Standard InChI Key: NTEQGRQRLWDRRP-LQLJQPJSSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 5006.73 | Molecular Weight (Monoisotopic): 5003.0854 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Upadhyaya P, Kristensson J, Lahdenranta J, Repash E, Ma J, Kublin J, Mudd GE, Luus L, Jeffrey P, Hurov K, McDonnell K, Keen N.. (2022) Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology., 65 (14.0): [PMID:35819182] [10.1021/acs.jmedchem.2c00505] |
Source(1):